Mark Hillman Hillman Capital Management
Mark Hillman is associated with Hillman Capital Management, a firm focused on fundamental equity research and long-term portfolio management. The firm’s public filings are followed by investors interested in actively managed, research-driven U.S. equity exposure. Hillman’s process emphasizes business analysis and valuation discipline rather than short-term trading.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zimmer Biomet
ZBH
|
+$6.43M |
| 2 |
Western Union
WU
|
+$6.22M |
| 3 |
Conagra Brands
CAG
|
+$3.51M |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$815K |
| 5 |
Air Products & Chemicals
APD
|
+$570K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$7.59M |
| 2 |
Simon Property Group
SPG
|
+$888K |
| 3 |
Microsoft
MSFT
|
+$850K |
| 4 |
Marriott International
MAR
|
+$591K |
| 5 |
AB InBev
BUD
|
+$529K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.86% |
| 2 | Communication Services | 12.83% |
| 3 | Industrials | 11.71% |
| 4 | Energy | 11.58% |
| 5 | Consumer Staples | 11.54% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Simon Property Group
SPG
$70.6B
| $11.7M | 4.01% |
73,088
-5,818
| -7% | -$888K |
|
2
CVS Health
CVS
$119B
| $11.3M | 3.87% |
109,098
-3,743
| -3% | -$346K |
|
3
Wells Fargo
WFC
$254B
| $11M | 3.77% |
228,546
-8,958
| -4% | -$441K |
|
|
4
Microsoft
MSFT
$3.59T
| $10.5M | 3.61% |
31,264
-2,622
| -8% | -$850K |
|
5
GSK
GSK
$105B
| $10.3M | 3.53% |
186,479
-6,942
| -4% | -$361K |
|
6
DuPont de Nemours
DD
$18.7B
| $10.2M | 3.51% |
100,715
-3,584
| -3% | -$341K |
|
7
Amazon
AMZN
$2.79T
| $9.95M | 3.42% |
59,660
-2,040
| -3% | -$349K |
|
|
K
8
DELISTED
Kellanova
K
| $9.83M | 3.38% |
162,509
-5,129
| -3% | -$303K |
|
9
Kraft Heinz
KHC
$30.3B
| $9.61M | 3.3% |
267,719
-8,341
| -3% | -$300K |
|
10
ExxonMobil
XOM
$679B
| $9.52M | 3.27% |
155,605
-7,980
| -5% | -$499K |
|
11
Enterprise Products Partners
EPD
$82.1B
| $9.17M | 3.15% |
417,790
-15,819
| -4% | -$355K |
|
12
Boeing
BA
$169B
| $8.91M | 3.06% |
44,235
-2,002
| -4% | -$423K |
|
|
13
AB InBev
BUD
$155B
| $8.79M | 3.02% |
145,234
-9,100
| -6% | -$529K |
|
14
Alphabet (Google) Class A
GOOGL
$4.22T
| $8.69M | 2.99% |
60,000
-200
| -0.3% | -$28.8K |
|
15
Intel
INTC
$476B
| $8.55M | 2.94% |
165,978
-4,653
| -3% | -$238K |
|
16
Bristol-Myers Squibb
BMY
$137B
| $8.35M | 2.87% |
133,937
-4,351
| -3% | -$255K |
|
|
BNY
17
Bank of New York Mellon
BNY
$108B
| $8.32M | 2.86% |
143,271
-928
| -0.6% | -$53.4K |
|
18
RTX Corp
RTX
$283B
| $8.13M | 2.79% |
94,439
-545
| -0.6% | -$47.5K |
|
19
Plains All American Pipeline
PAA
$17.4B
| $8.07M | 2.77% |
863,957
-28,790
| -3% | -$289K |
|
20
AT&T
T
$173B
| $7.82M | 2.69% |
420,705
-7,694
| -2% | -$144K |
|
21
Merck
MRK
$376B
| $7.56M | 2.6% |
98,696
-1,041
| -1% | -$82.9K |
|
22
Verizon
VZ
$205B
| $7.15M | 2.46% |
137,632
-676
| -0.5% | -$35.3K |
|
23
Meta Platforms (Facebook)
META
$1.4T
| $7.14M | 2.46% |
21,233
-126
| -0.6% | -$41.8K |
|
24
Compass Minerals
CMP
$1.09B
| $7.14M | 2.45% |
139,757
-7,441
| -5% | -$454K |
|
25
General Dynamics
GD
$104B
| $7.03M | 2.42% |
33,723
-245
| -0.7% | -$49.5K |
|
Similar funds
Mark Hillman's Q4 2021 Portfolio in Review
As of Q4 2021, Mark Hillman held 58 positions worth $291M, up 2.1% from $285M the previous quarter. Its ten largest holdings account for 36% of the portfolio.
Mark Hillman's Q4 2021 filing shows 7 new, 5 increased, 42 reduced and 4 closed positions. Its largest new stake was Air Products & Chemicals: 1,943 shares worth $591K. The largest sale was Pfizer, an estimated $7.59M.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 20% a quarter earlier, followed by Communication Services and Industrials.
- Mark Hillman's largest Q4 2021 buy was Air Products & Chemicals: 1,943 shares worth $591K.
- Mark Hillman added most to Zimmer Biomet in Q4 2021, an estimated $6.43M increase.
- Mark Hillman's biggest Q4 2021 reduction was Simon Property Group, cutting an estimated $888K.
- Mark Hillman fully exited Pfizer in Q4 2021, selling an estimated $7.59M.
- Mark Hillman's ten largest holdings make up 36% of its $291M portfolio in Q4 2021.
- Mark Hillman opened 7 new positions and closed 4 in Q4 2021.
- Mark Hillman's portfolio value rose 2.1% quarter-over-quarter to $291M.
Based on Hillman Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.